Improving the treatment of tropical infectious diseases

To counter the threat of antimalarial drug resistance emerging from the Greater Mekong sub-region recommendations have been made to switch to triple artemisinin combination treatments and developed the methods to conduct targeted malaria elimination in endemic areas. This study proposes a series of studies to assess the safety, efficacy and overall benefit of these new approaches. To support control and elimination the study will develop and evaluate better methods of identifying, measuring and monitoring antimalarial drug resistance. To prevent relapses of vivax malaria (the main therapeutic challenge and obstacle to elimination) it will investigate safer methods of giving primaquine, and identify the optimum dose of tafenoquine. This project will improve methods for the pharmacometric assessment of antimalarial drugs and will apply similar proven principles to the assessment of much needed treatments of Chagas disease and COVID-19. This is necessary to inform the choice of drug and dose in larger phase 3 assessments, accelerating their development.

Combination of Interventions

Apr 2022 — Oct 2025

$3.46M

United Kingdom